Bristol-Myers Squibb (BMS)

This sponsor has funded 39 studies across 25 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
2723 Finalised A Multi-National, Prospective, Observational Study in Patients with Unresectable or Metastatic Melanoma (IMAGE) No No
4700 Finalised Risk of stroke and other cardiovascular events among warfarin-treated atrial fibrillation patients – a nationwide cohort study in Finland (FinWAF) Yes Yes
4924 Finalised YERVOY Risk Minimisation Tool Evaluation Survey No No
5177 Finalised POST-APPROVAL SAFETY STUDY (PASS) OF THE UTILIZATION PATTERN OF APIXABAN IN SWEDEN Yes Yes
5184 Finalised POST-APPROVAL SAFETY STUDY (PASS) OF THE UTILIZATION PATTERN OF APIXABAN IN THE NETHERLANDS Yes Yes
6033 Finalised Ipilimumab 12-month intensive pharmacovigilance protocol No No
8718 Finalised Post-marketing Study Assessing the Long-term Safety of Abatacept No No
10046 Finalised Evaluation of the effectiveness of the belatacept (Nulojix®) Patient Alert Card in patients following renal transplantation in European Economic Area... No No
10122 Finalised Evaluation of the effectiveness of the abatacept (ORENCIA®) intravenous and subcutaneous formulation Patient Alert Cards in patients with rheumatoid... No Yes
10443 Finalised Evaluation of the effectiveness of Eliquis® (apixaban) risk minimization tools in European No No
10691 Finalised Disease progression and resource utilization in treated relapse/refractory multiple myeloma in Spain (PREMIERE) No No
11313 Finalised Comparative risk of major bleeding with new oral anticoagulants (NOACs) and Phenprocoumon in patients with atrial fibrillation: a retrospective claims... Yes No
11521 Finalised Benefit and risk of AntiThrombotic Treatments after Orthopaedic Surgery in real-life settings: a cohort study in the SNIIRAM claims and... No No
14071 Ongoing Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice (CA209234) No No
14786 Finalised Post-Authorisation Safety Study (PASS) of the Utilisation Patterns of Apixaban in Denmark Yes Yes
18323 Finalised Comparative risk of major bleeding with new oral anticoagulants (NOACs) and Phenprocoumon in patients with atrial fibrillation – effectiveness... Yes Yes
18444 Ongoing OBSERVATIONAL COHORT STUDY TO CHARACTERIZE THE SAFETY OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR PATIENTS WITH CLASSICAL HODGKIN... No No
18596 Finalised A Global Enhanced Pharmacovigilance Pregnancy Surveillance Study of Pregnant Women Exposed to Yervoy® with 5-year Pediatric Follow-up (CA184-487) No No
20861 Planned Retrospective Chart Review Study of First-Line Treatment Patterns and Clinical Outcomes in Patients with Advanced (Unresectable or Metastatic)... No No
25305 Finalised Real-world Evidence of Prolonged Apixaban Treatment of Unprovoked Venous Thromboembolism Yes Yes
25308 Finalised Evaluation of Anticoagulants among Venous Thromboembolism Patients with Active Cancer: Pooled Analysis from Claims Databases Yes Yes
25405 Ongoing Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study No No
25626 Ongoing Long-term non-interventional monitoring of patients newly diagnosed with bronchogenic carcinoma (LUCAS) No No
29722 Ongoing Long-term Follow-up of Ipilimumab-treated Pediatric Patients Enrolled in the Dutch Melanoma Treatment Registry (DMTR) No No
29910 Ongoing Venous Thromboembolism Treatment (VOLT) No No
29920 Planned Preferences of patients and oncologists for the characteristics of the treatment for RCC in Spain and Portugal No No
30299 Planned INVESTIGATING SECULAR TRENDS IN THE SURVIVAL OF MELANOMA PATIENTS IN ENGLAND Yes No
31529 Ongoing A Nationwide Post-Marketing Study on the Safety of Abatacept Treatment in Sweden Using the SRQ Register No No
31532 Ongoing A Nationwide Post-Marketing Study on the Safety of Abatacept Treatment in Denmark Using the DANBIO Register No No
32365 Finalised Evaluation of the Safety and Effectiveness of Anticoagulants Among Sub-Groups of Venous Thromboembolism Patients (VTE Subgroups) Yes Yes
35888 Ongoing Anticoagulant treatment patterns and outcomes among venous thrombosis patients in France: a retrospective cohort analysis using SNDS database No No
44059 Ongoing OPTIMISE:MS A Prospective, Real World Pharmacovigilance Study in Multiple Sclerosis Yes No
44615 Ongoing ORION (Ozanimod Real-World Safety - A Post-Authorisation Multi-National Long-term Non-Interventional Study) No No
45152 Ongoing Non-interventional Post-authorization Safety Study (PASS) of Patients Treated with Idecabtagene Vicleucel (ide-cel, BB2121) for Multiple Myeloma (MM)... Yes No
103852 Planned Non-interventional, post-authorization efficacy study to assess the consistency of Breyanzi product quality and clinical outcomes in patients treated... Yes No
103855 Ongoing Non-interventional, post-authorization safety study (PASS) of patients treated with commercially available liso-cel (lisocabtagene maraleucel) for... Yes No
104661 Planned Immunological adverse effects of immune checkpoint inhibitors (ICIMMUN) No No
107906 Planned Long-term follow-up of pediatric patients exposed to nivolumab + relatlimab fixed-dose combination (FDC) enrolled in the Dutch Melanoma Treatment... No No
108178 Planned Mavacamten Real-World Safety: a post-authorisation multi-national, long-term, observational study in patients with obstructive Hypertrophic... No No

PAS by Risk Management Plan (RMP) requirement

Bristol-Myers Squibb (BMS)

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.